Keytruda (pembrolizumab) + chemoradiotherapy (CRT) significantly improved overall survival versus CRT alone in patients with newly diagnosed high-risk locally advanced cervical cancer.- Merck Inc.,
Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating Keytruda, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) met its primary endpoint of overall survival (OS) for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer.